Stockscreener 앱 받기
28.98
1.31%
0.375
시간 외 거래:
28.99
0.005
+0.02%
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes (ALKS) Upgraded by UBS with Positive Development Prospe - GuruFocus
Alkermes stock upgraded at UBS on sleep disorder drug (ALKS) - Seeking Alpha
Alkermes Gains Momentum With Promising Narcolepsy Drug - Finimize
Alkermes' ALKS-2680 Seen as Potential Breakthrough for Narcolepsy, Hypersomnia, BofA Says - MarketScreener
Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | A - GuruFocus
Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | ALKS Stock News - GuruFocus
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stoc - GuruFocus
This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga
Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stock News - GuruFocus
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33 - marketscreener.com
Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narco - GuruFocus
Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narcolepsy Treatment | ALKS Stock News - GuruFocus
When (ALKS) Moves Investors should Listen - news.stocktradersdaily.com
Substance Abuse Treatment Market Size, Trends & Growth - openPR.com
Insider Sell: Christian Nichols Sells Shares of Alkermes PLC - GuruFocus
RBC Capital maintains Alkermes stock rating amid safety concerns By Investing.com - Investing.com Nigeria
GAMMA Investing LLC Grows Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Transcript : Alkermes plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
Alkermes at Goldman Sachs Healthcare: Strategic Moves in Sleep Disorders By Investing.com - Investing.com Nigeria
Alkermes at Goldman Sachs Healthcare: Strategic Moves in Sleep Disorders - Investing.com Australia
Alkermes To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Fed. Circ. Weighs Purview Over Acorda's $17M Arbitral Award - Law360
Substance Abuse Treatment Market Set to Witness Digital and Personalized Care Expansion | Indivior, Alkermes - openPR.com
Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com
Nanotechnology Drug Delivery Market Set to Witness Significant - openPR.com
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - The Malaysian Reserve
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - StreetInsider
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | ALKS Stock News - GuruFocus
Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation? - simplywall.st
Where are the Opportunities in (ALKS) - news.stocktradersdaily.com
Cetera Investment Advisers Increases Stock Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 20 - GuruFocus
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 2025 | ALKS Stock News - GuruFocus
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - goSkagit
Global Healthcare & Medical Tourism News - Medical Tourism Magazine
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sal - GuruFocus
Needham Initiates Alkermes Public at Buy With $45 Price Target - marketscreener.com
Needham Initiates Coverage on Alkermes (ALKS) with Buy Rating | ALKS Stock News - GuruFocus
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sales Projections | ALKS Stock News - GuruFocus
Quantinno Capital Management LP Acquires New Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Controlled Release Drug Delivery Market Generated - openPR.com
Bank of America Corp DE Trims Stake in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes Shareholders Approve Amendments at Annual Meeting - TipRanks
(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alkermes price target raised to $35 from $34 at BofA - MSN
Captrust Financial Advisors Raises Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Nanotechnology Drug Delivery Market Generated Opportunities, - openPR.com
1.05%
0.60%
자본화:
|
볼륨(24시간):